Rodman Arranges 30th PIPE for Cancer Drug Developer Cell Therapeutics
Posted by The PIPEs Report on December 9, 2011
Rodman & Renshaw is arranging the 30th PIPE financing for cancer drug developer Cell Therapeutic…
Source >>>
Cancer Drug Maker Goes Public, Raises $55M in Reverse Merger
Posted by admin on October 6, 2011
Puma Biotechnology, a Los Angeles biotechnology company making treatments for cancer, agreed to go p…
Source >>>
Cancer Drug Maker Goes Public, Raises $55M in Reverse Merger
Posted by The PIPEs Report on
Puma Biotechnology, a Los Angeles biotechnology company making treatments for cancer, agreed to go p…
Source >>>
Rodman Raising $12.7M in 16th PIPE for Cancer Drug Maker Genta
Posted by The PIPEs Report on September 6, 2011
Rodman & Renshaw is arranging a $12.7 million private placement of convertible debt for Genta In…
Source >>>
Rodman Arranges $18.4M for Cancer Drug Developer Celsion
Posted by The PIPEs Report on July 21, 2011
Rodman & Renshaw arranged $18.4 million in private placement financing for cancer drug developer Cel…
Source >>>
Venture Capitalist Duggan Among Investors of $57M in Cancer Drug Maker
Posted by The PIPEs Report on June 17, 2011
Venture capitalist Robert Duggan is among the investors in a $57 million registered direct offering …
Source >>>
AVEO Pharma Raises $100.6M in Registered Direct
Posted by The PIPEs Report on June 15, 2011
Cancer drug maker AVEO Pharmaceuticals (AVEO) raised $100.6 million from the sale of 5.75 million sh…
Source >>>
AVEO Pharma Raises $100.6M in Registered Direct
Posted by The PIPEs Report on
Cancer drug maker AVEO Pharmaceuticals (AVEO) raised $100.6 million from the sale of 5.75 million sh…
Source >>>
Rodman Arranging 28th PIPE for Cancer Drug Specialist Cell Therapeutics
Posted by The PIPEs Report on April 28, 2011
Rodman & Renshaw is arranging a $16 million registered direct offering of convertible preferred …
Source >>>
Lost flu sales weigh on Roche and other pharmas in Q1
Posted by Reuters: Business News on April 11, 2011
LONDON (Reuters) – Roche is set to kick off the Big Pharma reporting season with a fall in sales on Thursday as a strong Swiss franc, weak demand for top-selling cancer drug Avastin and lack of Tamiflu revenue take their toll.
